Narayana Hrudayalaya Ltd. (NH) — Financial Results

Investor Takeaways

Revenue of ₹1,366.68 Cr in Q3FY25, up from ₹1,279.42 Cr in Q4FY24, indicating sequential growth.

Net profit of ₹193.05 Cr in Q3FY25, compared to ₹190.78 Cr in Q4FY24, showing a marginal increase.

OPM of 22.46% in Q3FY25, slightly down from 23.02% in Q4FY24 but within a stable range.

₹37,624.87 Cr market cap, with a P/E ratio of 47.71, reflecting market valuation relative to earnings.

Overall Tone: Neutral based on the numbers only.

Key Financial Highlights

Metric	Value	YoY Change
Revenue	₹1,366.68 Cr	+6.78% (Q3FY25 vs Q4FY24)
Net Profit	₹193.05 Cr	+1.20% (Q3FY25 vs Q4FY24)
EBITDA	Not available	N/A
EPS	[amount context mismatch]	-4.08% (Q3FY25 vs Q2FY25)
OPM	22.46%	-2.38% (Q3FY25 vs Q4FY24)

What Changed

The company reported revenue of ₹1,366.68 Cr in Q3FY25, up from ₹1,279.42 Cr in the previous quarter (Q4FY24), reflecting a 6.78% sequential increase. Net profit rose marginally to ₹193.05 Cr from ₹190.78 Cr, a 1.20% growth. However, operating profit margin (OPM) declined to 22.46% from 23.02% in Q4FY24, indicating slight pressure on margins despite revenue growth. Earnings per share (EPS) stood at ₹9.5 in Q3FY25, down 4.08% from ₹9.92 in Q2FY25, suggesting a temporary dip in profitability per share. The company’s market capitalization of ₹37,624.87 Cr and P/E ratio of 47.71 indicate a premium valuation relative to peers, though no direct peer comparison of P/E is provided in the data. Quarterly performance shows consistent revenue and profit levels over the last four quarters, with minor fluctuations in margins and EPS. No specific risks or concerns were highlighted in the filing, and the financial trends remain stable without significant deviations.

Peer Comparison

Company	P/E	ROE	ROCE	Market Cap (₹ Cr)
NH	47.71	Not available	Not available	37,624.87
SUNPHARMA	41.28	15.11%	20.34%	4,50,643.09
DIVISLAB	72.41	16.56%	22.09%	1,79,470.03
TORNTPHARM	80.06	N/A	N/A	1,49,108.91

NH’s P/E ratio of 47.71 is lower than DIVISLAB’s 72.41 and TORNTPHARM’s 80.06 but higher than SUNPHARMA’s 41.28. The company’s market cap is significantly smaller than SUNPHARMA’s ₹4,50,643.09 Cr but larger than DIVISLAB’s ₹1,79,470.03 Cr. No ROE or ROCE data was provided for NH in the fundamentals, limiting direct comparison on efficiency metrics.